Modality
Bispecific Ab
MOA
CD3xCD20
Target
MALT1
Pathway
STING
PsoriasisMG
Development Pipeline
Preclinical
Aug 2021
PreclinicalCurrent
NCT08096927
2,150 pts·Psoriasis
2021-08→TBD·Completed
2,150 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-02-072mo agoAdCom· Psoriasis
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
Preclinical
Complet…
Catalysts
AdCom
2026-02-07 · 2mo ago
Psoriasis
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08096927 | Preclinical | Psoriasis | Completed | 2150 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 |